NASDAQ:CTIC CTI BioPharma (CTIC) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$9.09▼$9.0950-Day Range$8.91▼$9.1052-Week Range$4.01▼$9.10VolumeN/AAverage Volume4.50 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$9.75 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media CTI BioPharma MarketRank™ ForecastAnalyst RatingHold2.29 Rating ScoreUpside/Downside7.3% Upside$9.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.25) to $0.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.79 out of 5 starsMedical Sector963rd out of 969 stocksPharmaceutical Preparations Industry448th out of 452 stocks 1.1 Analyst's Opinion Consensus RatingCTI BioPharma has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.75, CTI BioPharma has a forecasted upside of 7.3% from its current price of $9.09.Amount of Analyst CoverageCTI BioPharma has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CTIC. Previous Next 0.0 Dividend Strength Dividend YieldCTI BioPharma does not currently pay a dividend.Dividend GrowthCTI BioPharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTIC. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for CTIC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CTI BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.61% of the stock of CTI BioPharma is held by insiders.Percentage Held by Institutions91.45% of the stock of CTI BioPharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CTI BioPharma are expected to grow in the coming year, from ($0.25) to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CTI BioPharma is -15.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CTI BioPharma is -15.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About CTI BioPharma (NASDAQ:CTIC) StockCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Read More CTIC Stock News HeadlinesAugust 23, 2023 | stockhouse.comSEC Charges Former Attorney at U.S.-Based Global Law Firm with Insider TradingJune 27, 2023 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi completes acquisition of CTI BioPharma Corp.October 2, 2023 | Porter and Company (Ad)Top Analyst Exposes Imminent Crisis Hurtling Towards AmericaThe man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…June 26, 2023 | finance.yahoo.comSobi completes acquisition of CTI BioPharma Corp.June 7, 2023 | markets.businessinsider.comCTI BioPharma (CTIC) was upgraded to a Hold Rating at Stifel NicolausMay 30, 2023 | markets.businessinsider.comStifel Nicolaus upgrades CTI BioPharma (CTIC) to a HoldMay 25, 2023 | finanznachrichten.deSwedish Orphan Biovitrum AB: Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.May 25, 2023 | finance.yahoo.comSobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.October 2, 2023 | Porter and Company (Ad)Top Analyst Exposes Imminent Crisis Hurtling Towards AmericaThe man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…May 24, 2023 | msn.comJMP Securities Maintains CTI BioPharma (CTIC) Market Perform RecommendationMay 24, 2023 | markets.businessinsider.comJMP Securities Keeps Their Hold Rating on CTI BioPharma (CTIC)May 16, 2023 | msn.comCTI BioPharma: $1.7bn M&A With 85% Premium, Expect The Deal To Go ThroughMay 16, 2023 | msn.comSVB Leerink Downgrades CTI BioPharma (CTIC)May 16, 2023 | markets.businessinsider.comSVB Securities downgrades CTI BioPharma (CTIC) to a HoldMay 16, 2023 | marketwatch.comSHAREHOLDER ALERT: Weiss Law Investigates CTI BioPharma Corp.May 15, 2023 | msn.comStifel Downgrades CTI BioPharma (CTIC)May 15, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for CTI BioPharmaMay 12, 2023 | msn.comNeedham Downgrades CTI BioPharma (CTIC)May 12, 2023 | msn.comUnusual Call Option Trade in CTI BioPharma (CTIC) Worth $312.39KMay 11, 2023 | reuters.comSweden's SOBI offers $1.7 bln to buy CTI BioPharmaMay 11, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating CTI BioPharma Corp. BuyoutMay 11, 2023 | markets.businessinsider.comCTI BioPharma (CTIC) was downgraded to a Hold Rating at JMP SecuritiesMay 10, 2023 | msn.comCTI BioPharma shares soar 83% after Swedish Orphan Biovitrum announces $1.7 billion deal for the biotechMay 10, 2023 | msn.comCTI BioPharma Soars on $1.7B Acquisition by Orphan BiovitrumMay 10, 2023 | bizjournals.comCTI BioPharma to be acquired by Swedish drug company for $1.7BMay 10, 2023 | finance.yahoo.comWhy Shares of CTI BioPharma Are Soaring WednesdayMay 10, 2023 | investorplace.comWhy Is CTI BioPharma (CTIC) Stock Up 85% Today?See More Headlines Receive CTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CTIC Company Calendar Last Earnings3/06/2023Today10/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTIC Previous SymbolNASDAQ:CTICD CUSIPN/A CIK891293 Webwww.ctibiopharma.com Phone(206) 282-7100Fax206-284-6206Employees127Year Founded1992Price Target and Rating Average Stock Price Forecast$9.75 High Stock Price Forecast$13.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+7.3%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,990,000.00 Net Margins-91.38% Pretax Margin-91.38% Return on EquityN/A Return on Assets-55.82% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.26 Sales & Book Value Annual Sales$53 million Price / Sales22.62 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-64.93Miscellaneous Outstanding Shares131,880,000Free Float121,844,000Market Cap$1.20 billion OptionableOptionable Beta0.83 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Adam R. Craig M.B.A. (Age 57)M.D., Ph.D., Pres, CEO, Interim Chief Medical Officer & Director Comp: $1.09MMr. David H. Kirske (Age 69)Exec. VP, CFO & Sec. Comp: $590.41kMr. James K. Fong (Age 61)Exec. VP & Chief Commercial Officer Comp: $597.3kMr. Ed BellSr. Director of Investor RelationsMr. Bruce K. Bennett Jr. (Age 71)Sr. VP Global Pharmaceutical Operations Mr. John P. VolponeExec. VP & Chief of StaffDr. Jennifer A. SmithSr. VP of BiometricsMore ExecutivesKey CompetitorsViking TherapeuticsNASDAQ:VKTXBiohavenNYSE:BHVNANI PharmaceuticalsNASDAQ:ANIPOPKO HealthNASDAQ:OPK89bioNASDAQ:ETNBView All CompetitorsInsiders & InstitutionsWolverine Trading LLCSold 12,500 shares on 8/23/2023Ownership: 0.000%Citadel Advisors LLCSold 42,800 shares on 8/15/2023Ownership: 0.000%Jefferies Financial Group Inc.Sold 40,000 shares on 8/14/2023Ownership: 0.000%Caption Management LLCSold 100,000 shares on 8/14/2023Ownership: 0.000%Simplex Trading LLCSold 32,400 shares on 8/4/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CTIC Stock - Frequently Asked Questions Should I buy or sell CTI BioPharma stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last twelve months. There are currently 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTIC, but not buy additional shares or sell existing shares. View CTIC analyst ratings or view top-rated stocks. What is CTI BioPharma's stock price forecast for 2023? 7 Wall Street research analysts have issued 12 month price objectives for CTI BioPharma's stock. Their CTIC share price forecasts range from $8.00 to $13.00. On average, they expect the company's share price to reach $9.75 in the next year. This suggests a possible upside of 7.3% from the stock's current price. View analysts price targets for CTIC or view top-rated stocks among Wall Street analysts. How were CTI BioPharma's earnings last quarter? CTI BioPharma Corp. (NASDAQ:CTIC) posted its earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to analyst estimates of $24.88 million. During the same period in the prior year, the business earned ($0.38) earnings per share. When did CTI BioPharma's stock split? CTI BioPharma's stock reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is James A. Bianco's approval rating as CTI BioPharma's CEO? 8 employees have rated CTI BioPharma Chief Executive Officer James A. Bianco on Glassdoor.com. James A. Bianco has an approval rating of 27% among the company's employees. This puts James A. Bianco in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of CTI BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other CTI BioPharma investors own include Edap Tms (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA (XOMA), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Vaxart (VXRT), Dynavax Technologies (DVAX) and Trevena (TRVN). What is CTI BioPharma's stock symbol? CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC." What is CTI BioPharma's stock price today? One share of CTIC stock can currently be purchased for approximately $9.09. How much money does CTI BioPharma make? CTI BioPharma (NASDAQ:CTIC) has a market capitalization of $1.20 billion and generates $53 million in revenue each year. The biopharmaceutical company earns $-92,990,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. How many employees does CTI BioPharma have? The company employs 127 workers across the globe. How can I contact CTI BioPharma? CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The official website for the company is www.ctibiopharma.com. The biopharmaceutical company can be reached via phone at (206) 282-7100, via email at invest@ctibiopharma.com, or via fax at 206-284-6206. This page (NASDAQ:CTIC) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CTI BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.